Literature DB >> 7063721

Recurrent pyogenic cholangitis in Asian immigrants. Use of ultrasonography, computed tomography, and cholangiography.

M P Federle, J P Cello, F C Laing, R B Jeffrey.   

Abstract

Five cases of recurrent pyogenic cholangitis (RPC) were studied by ultrasonography, computed tomography (CT), and cholangiography. All patients were recent immigrants from the Orient or Indonesia and had had recurrent attacks of cholangitis for many years. The bile was infected by E. coli and the biliary ducts were dilated; in addition, extrahepatic bile-pigment calculi were present in all 5 and intrahepatic calculi in 4. Abdominal ultrasound usually failed to demonstrate duct calculi and extrahepatic dilatation due to the soft, mud-like consistency of the stones. CT was successful in showing the calculi and the full extent of dilatation. The authors conclude that preoperative diagnosis of RPC is best achieved by awareness of the characteristic clinical presentation and the findings on abdominal CT. Preoperative cholangiography provides excellent detail, but poses the danger of biliary sepsis requiring antibiotics.

Entities:  

Mesh:

Year:  1982        PMID: 7063721     DOI: 10.1148/radiology.143.1.7063721

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  3 in total

1.  Recurrent pyogenic cholangitis in a white woman.

Authors:  Simon Bergman; Antonio Di Carlo; Prosanto Chaudhury; Carl Blum; Ayoub Nahal; Peter Metrakos
Journal:  Can J Surg       Date:  2007-10-10       Impact factor: 2.089

2.  Treatment of postoperative residual hepatolithiasis after progressive stenting of associated bile duct strictures through the T-tube tract.

Authors:  Y F Cheng; T Y Chen; S F Ko; C C Huang; T L Huang; H H Weng; T Y Lee; S M Sheen-Chen
Journal:  Cardiovasc Intervent Radiol       Date:  1995 Mar-Apr       Impact factor: 2.740

3.  Recurrent pyogenic cholangitis treated by left hepatectomy.

Authors:  Sukanta Ray
Journal:  Indian J Surg       Date:  2011-04-15       Impact factor: 0.656

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.